AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg daily for 6 months
Number of subjects: 60
Study 3052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 6 months
Number of subjects: 60
Study 3052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for cyclical pain
Number of subjects: 60
Study 3052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for non-cyclical pain
Number of subjects: 60
Study 31134226 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass Carbomer (GC)
Number of subjects: 162
Study 31134226 — intervention group
Group type: COMPARATOR
Intervention: Resin‐modified glass‐ionomer cement (RMGIC)
Number of subjects: 162
Study 31134226 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (CR)
Number of subjects: 162
Study 29412185 — intervention group
Group type: COMPARATOR
Intervention: Day Surgery setting
Number of subjects: 112
Study 29412185 — intervention group
Group type: COMPARATOR
Intervention: Outpatient setting
Number of subjects: 112
Study 29412185 — intervention group
Group type: COMPARATOR
Intervention: Outpatient setting (patients over 65 years)
Number of subjects: 112
Study 27592112 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NAC)
Number of subjects: 188
Study 24797871 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP counseling
Number of subjects: 600
Study 24797871 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet
Number of subjects: 600
Study 22189657 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine infusion
Number of subjects: 15
Study 22189657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21305729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 mL
Number of subjects: 60
Study 21305729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 mL and 2 mg/0.05 mL
Number of subjects: 60
Study 21305729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study 18251159 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min Pringle maneuver with gabexate mesilate (GM, 2 mg/kg/h)
Number of subjects: 120
Study 18251159 — intervention group
Group type: COMPARATOR
Intervention: 15‐min Pringle maneuver with gabexate mesilate (GM, 2 mg/kg/h)
Number of subjects: 120
Study 18251159 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min Pringle maneuver without gabexate mesilate (GM)
Number of subjects: 120
Study 18251159 — intervention group
Group type: COMPARATOR
Intervention: 15‐min Pringle maneuver without gabexate mesilate (GM)
Number of subjects: 120
Study 16297750 — intervention group
Group type: COMPARATOR
Intervention: Group B (44 patients) - Intraoperative anesthetic management was blinded to BIS values.
Number of subjects: 121
Study 16297750 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (41 patients) - Anesthesiologist observing the BIS monitor informed the attending anesthesiologist about the BIS score.
Number of subjects: 121
Study 16297750 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (36 patients) - Continuous access to BIS information.
Number of subjects: 121
Study 12089888 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetric parameters in children with urinary tract infections
Number of subjects: 379
Study 12089888 — intervention group
Group type: COMPARATOR
Intervention: Control group (195 patients)
Number of subjects: 379
Study 10816746 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated Olyset Net mosquito nets
Number of subjects: 0
Study 8574280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (30 mg)
Number of subjects: 9
Study 8574280 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (2.5 mg)
Number of subjects: 9
Study 8574280 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (5 mg)
Number of subjects: 9
Study 8574280 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (10 mg)
Number of subjects: 9
Study 8574280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2302146 — intervention group
Group type: EXPERIMENTAL
Intervention: Underpredicted pain
Number of subjects: 0
Study 540445 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete bed rest for 24 hours
Number of subjects: 10
Study 31816249 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 667
Study 31816249 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 667
Study 31816249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 31816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall erenumab-treated population
Number of subjects: 667
Study 31816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Not achieving ≥50% response
Number of subjects: 667
Study 31816249 — intervention group
Group type: EXPERIMENTAL
Intervention: Not achieving ≥75% response
Number of subjects: 667
Study 29948221 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44 gene expression and DNA methylation levels in low responders (LR)
Number of subjects: 47
Study 29948221 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44 protein levels measured by ELISA in human plasma
Number of subjects: 47
Study 28763443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT) in a normobaric hypoxia environment (FiO2 = 15.5%)
Number of subjects: 16
Study 28763443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 16
Study 28763443 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxic training)
Number of subjects: 16
Study 24761786 — intervention group
Group type: EXPERIMENTAL
Intervention: Social consequences framed as a loss
Number of subjects: 124
Study 24761786 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consequences framed as a gain
Number of subjects: 124
Study 24761786 — intervention group
Group type: EXPERIMENTAL
Intervention: Social consequences framed as a gain
Number of subjects: 124
Study 24761786 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consequences framed as a loss
Number of subjects: 124
Study 24761786 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 124
Study 25065452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment
Number of subjects: 75
Study 25065452 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 75
Study 22829944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of statins (rosuvastatin or atorvastatin) and regular exercise
Number of subjects: 28
Study 19168602 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (250 mg/day to 2000 mg/day for 6 weeks)
Number of subjects: 18
Study 19168602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17487770 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-to-edge repair with De Vega annuloplasty (group E)
Number of subjects: 57
Study 17487770 — intervention group
Group type: COMPARATOR
Intervention: Modified De Vega annuloplasty alone (group D)
Number of subjects: 57
Study 14678341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 16
Study 14678341 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 16
Study 12499479 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic leg movements (PLM) in idiopathic REM sleep behavior disorder (RBD)
Number of subjects: 40
Study 12499479 — intervention group
Group type: EXPERIMENTAL
Intervention: PLM features and PLMS-related cardiac activation during stage 2 sleep
Number of subjects: 40
Study 12499479 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMS associated with microarousal
Number of subjects: 40
Study 12499479 — intervention group
Group type: EXPERIMENTAL
Intervention: PLMS frequency during REM sleep
Number of subjects: 40
Study 12499479 — intervention group
Group type: EXPERIMENTAL
Intervention: PLM mean duration and interval
Number of subjects: 40
Study 12499479 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PLMS in RBD and RLS
Number of subjects: 40
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical chromosome 16 aberrations in primary tumors
Number of subjects: 53
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical chromosome 16 aberrations in metastatic tumors
Number of subjects: 53
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: 16q deletion in primary tumors
Number of subjects: 53
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: 16q deletion in metastatic tumors
Number of subjects: 53
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of E-cadherin expression in primary tumors
Number of subjects: 53
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of E-cadherin expression in metastatic tumors
Number of subjects: 53
Study 9650913 — intervention group
Group type: EXPERIMENTAL
Intervention: High tumor grade and DNA aneuploidy correlation with metastases
Number of subjects: 53
Study 8748046 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 10
Study 8748046 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB + naloxone
Number of subjects: 10
Study 8748046 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB + metergoline
Number of subjects: 10
Study 8748046 — intervention group
Group type: COMPARATOR
Intervention: Placebo + saline
Number of subjects: 10
Study 2702460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressings applied until the time of suture removal
Number of subjects: 1202
Study 2702460 — intervention group
Group type: COMPARATOR
Intervention: No dressings after the first postoperative day
Number of subjects: 1202
Study 545993 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume loading to a mean pulmonary artery occlusion pressure (MPAOP) of 16 mmHg (2.13 kPa) before declamping
Number of subjects: 19
Study 545993 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained at an average MPAOP of 11 mmHg (1.46 kPa) before declamping
Number of subjects: 19
Study 30865791 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimen (9 to 11 months) including high-dose moxifloxacin
Number of subjects: 424
Study 30865791 — intervention group
Group type: COMPARATOR
Intervention: Long regimen (20 months) following WHO guidelines
Number of subjects: 424
Study 27860212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 147
Study 27860212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake (fibre, carbohydrates, fat)
Number of subjects: 147
Study 25467012 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL hydrochloride 5%
Number of subjects: 262
Study 25467012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 23532799 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET
Number of subjects: 86
Study 23532799 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 86
Study 17317747 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy elderly individuals (loop gain <= 0.25)
Number of subjects: 14
Study 17317747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly individuals with obstructive sleep apnoea (loop gain <= 0.26)
Number of subjects: 14
Study 17317747 — intervention group
Group type: COMPARATOR
Intervention: Young individuals (loop gain <= 0.47)
Number of subjects: 14
Study 15235926 — intervention group
Group type: EXPERIMENTAL
Intervention: Baked skim soy with soy sauce (protein, 86.9 g)
Number of subjects: 6
Study 15235926 — intervention group
Group type: EXPERIMENTAL
Intervention: Beefsteak (200 g)
Number of subjects: 6
Study 10980457 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular fluticasone (250 microg twice daily for two weeks)
Number of subjects: 10
Study 10980457 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fluticasone (250 microg 30 min before allergen inhalation)
Number of subjects: 10
Study 10980457 — intervention group
Group type: COMPARATOR
Intervention: Single placebo
Number of subjects: 10
Study 10980457 — intervention group
Group type: COMPARATOR
Intervention: Regular placebo
Number of subjects: 10
Study 8831994 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC) transplantation in AML patients
Number of subjects: 44
Study 8831994 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood stem cells (PBSC) transplantation in patients with other diseases
Number of subjects: 44
Study 1424488 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 72
Study 1424488 — intervention group
Group type: COMPARATOR
Intervention: Acylureide penicillins
Number of subjects: 72
Study 2413692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin applied under occlusion
Number of subjects: 15
Study 2413692 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied under occlusion
Number of subjects: 15
Study 31030961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz spinal cord stimulation
Number of subjects: 120
Study 31030961 — intervention group
Group type: COMPARATOR
Intervention: α‐bungarotoxin (α7 nicotinic acetylcholine receptor antagonist)
Number of subjects: 120
Study 31030961 — intervention group
Group type: COMPARATOR
Intervention: 2 Hz spinal cord stimulation + α‐bungarotoxin
Number of subjects: 120
Study 31030961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 30476490 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC sheets plus PRF (group A)
Number of subjects: 4
Study 30476490 — intervention group
Group type: COMPARATOR
Intervention: ASC sheets only (group B)
Number of subjects: 4
Study 30476490 — intervention group
Group type: COMPARATOR
Intervention: PRF only (group C)
Number of subjects: 4
Study 30476490 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 4
Study 29046172 — intervention group
Group type: EXPERIMENTAL
Intervention: New symbology for obstacles
Number of subjects: 21
Study 29046172 — intervention group
Group type: COMPARATOR
Intervention: Old symbols
Number of subjects: 21
Study 25795717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions for counts <10×10(9)/L
Number of subjects: 0
Study 25795717 — intervention group
Group type: COMPARATOR
Intervention: No-prophylaxis
Number of subjects: 0
Study 25795717 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature of at least 38°C
Number of subjects: 0
Study 25795717 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with platelet count <10×10(9)/L
Number of subjects: 0
Study 23851346 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg, 1‐h IV infusion) with cyclosporine (5 mg/kg, 2‐h infusion)
Number of subjects: 14
Study 23851346 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg, 1‐h IV infusion) without cyclosporine (control)
Number of subjects: 14
Study 20204535 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto bi-level device with pressure relief during exhalation
Number of subjects: 35
Study 20204535 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 35
Study 19207890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical periodontal treatment with local application of minocycline (APT)
Number of subjects: 27
Study 19207890 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal maintenance (PM)
Number of subjects: 27
Study 19207890 — intervention group
Group type: COMPARATOR
Intervention: Mechanical tooth cleaning (MPT)
Number of subjects: 27
Study 16790163 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic liaison service
Number of subjects: 317
Study 16790163 — intervention group
Group type: COMPARATOR
Intervention: Traditional psychotherapeutic consultation
Number of subjects: 317
Study 12735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Smear layer removed
Number of subjects: 30
Study 12735922 — intervention group
Group type: EXPERIMENTAL
Intervention: Smear layer present
Number of subjects: 30
Study 12735922 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 30
Study 11072773 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack weighing 25 kg
Number of subjects: 20
Study 11072773 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack weighing 35 kg
Number of subjects: 20
Study 11072773 — intervention group
Group type: COMPARATOR
Intervention: Unladen (no backpack)
Number of subjects: 20
Study 11072773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient increase
Number of subjects: 20
Study 9532461 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of bleeding group (n = 172)
Number of subjects: 328
Study 9532461 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of plaque group (n = 156)
Number of subjects: 328
Study 8256504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination with Recombivax HB
Number of subjects: 0
Study 8256504 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of Recombivax HB given at 3 or 4 years
Number of subjects: 0
Study 8256504 — intervention group
Group type: COMPARATOR
Intervention: Initial response to vaccination
Number of subjects: 0
Study 2864153 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin treatment
Number of subjects: 18
Study 2864153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31547844 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration catheter (group A, n=101)
Number of subjects: 204
Study 31547844 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilatation (group B, n=103)
Number of subjects: 204
Study 28840422 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Number of subjects: 163
Study 28840422 — intervention group
Group type: EXPERIMENTAL
Intervention: Elobixibat 15 mg
Number of subjects: 163
Study 28840422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 27465384 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 52
Study 27465384 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EX)
Number of subjects: 52
Study 27465384 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction and Exercise combined (CREX)
Number of subjects: 52
Study 27465384 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 52
Study 25551953 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 24
Study 25551953 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene sutures
Number of subjects: 24
Study 25551953 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 24
Study 22626743 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 200
Study 22626743 — intervention group
Group type: COMPARATOR
Intervention: Standard patient management
Number of subjects: 200
Study 20802250 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 60,000 IU i.v. bolus within 3 hours after PCI
Number of subjects: 529
Study 20802250 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care alone (Control)
Number of subjects: 529
Study 20802250 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 529
Study 18852398 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d
Number of subjects: 316
Study 18852398 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d (metformin monotherapy cohort)
Number of subjects: 316
Study 18852398 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d (combination therapy cohort)
Number of subjects: 316
Study 18852398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 16088820 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (nevirapine, lamivudine, and zidovudine) for a median of 98 days (range, 67-222 days)
Number of subjects: 51
Study 16088820 — intervention group
Group type: COMPARATOR
Intervention: No HAART (control group)
Number of subjects: 51
Study 16088820 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (nevirapine, lamivudine, and zidovudine)
Number of subjects: 51
Study 12064336 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggshell powder-enriched supplement (group A; n=24)
Number of subjects: 85
Study 12064336 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified CaCO3-enriched supplement (group B; n=22)
Number of subjects: 85
Study 12064336 — intervention group
Group type: COMPARATOR
Intervention: Placebo product (group C; n=27)
Number of subjects: 85
Study 10598691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily
Number of subjects: 242
Study 10598691 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of 2% dorzolamide (three times daily) and 0.5% timolol (twice daily)
Number of subjects: 242
Study 10598691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily during open-label extension
Number of subjects: 242
Study 8707080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g twice daily
Number of subjects: 14
Study 8707080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8707080 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg twice daily
Number of subjects: 14
Study 8707080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine 1 g twice daily
Number of subjects: 14
Study 1684492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.025%, 0.05%, 0.1%, and 0.2% (topical administration)
Number of subjects: 0
Study 1684492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.1% (multiple doses)
Number of subjects: 0
Study 1684492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.1% (single application)
Number of subjects: 0
Study 1684492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride
Number of subjects: 0
Study 7067358 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading of the whole of inspiration
Number of subjects: 10